At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Richard Henry, President Elect of the UKONS, and Teaching Fellow at the School of Nursing and Midwifery, Queen’s University Belfast, Belfast, UK, explains the purpose of the UKONS, which includes promoting high standards in the nursing management and care of individuals affected by cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
Author: Editor
Natalie Doyle, MSc, RGN, Nurse Consultant at The Royal Marsden NHS Foundation Trust, London, UK, discusses the aims of the United Kingdom Oncology Nursing Society (UKONS), which is run by cancer nurses for cancer nurses, and the UKONS Annual Conference 2015. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Rihannon Skilton, Head of Support Line Services, Tenovus Cancer Care, Cardiff, Wales, discusses the impact of the Tenovus Cancer Care Sing with Us choirs, which are open to anyone affected by cancer, on those that participate. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Natalie Doyle, MSc, RGN, Nurse Consultant at The Royal Marsden NHS Foundation Trust, London, UK, explains the potential benefits of lifestyle choices, including interventions on diet and physical activity, for cancer patients. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Hilary Glen, MbChB, MSc, PhD, FRCP, of the Beatson West of Scotland Cancer Centre, Glasgow, UK, reviews the scientific and societal challenges of drug development for the treatment of patients with metastatic castration-resistant prostate cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
Jeff Sharman, MD Medical Director of Hematology Research for US Oncology discusses Ibrutinib or Idelalisib Selecting Appropriate Therapy for Relapsed CLL
Jeff Sharman, MD Medical Director of Hematology Research for US Oncology discusses Entospletinib Why Its Different Than Fostamatinib
Jeff Sharman, MD Medical Director of Hematology Research for US Oncology talks about how CLL has been Transformed in Last 5 Years and that the Hope is to Leave Chemotherapy Behind
Jeff Sharman, MD Medical Director of Hematology Research for US Oncology discusses ASH 2015 highlights as Bcl-2, BTK, and PI3 Inhibitors
Susan M. OBrien, MD Medical Director of the Sue and Ralph Stern Center for Cancer Clinical Trials and Research UC Irvine talks about how Venetoclax Produces Good Responses for 17p Deletion May Be Approved in 2016
Susan M. OBrien, MD Medical Director of the Sue and Ralph Stern Center for Cancer Clinical Trials and Research UC Irvine discusses how Idelalisib + Rituximab is Successful in Frontline but with Some Toxicity
Susan M. OBrien, MD Medical Director of the Sue and Ralph Stern Center for Cancer Clinical Trials and Research UC Irvine discusses Ibrutinib or Idelalisib Preferred in Relapsed Patients Over Chemotherapy for CLL.
Susan M. OBrien, MD Medical Director of the Sue and Ralph Stern Center for Cancer Clinical Trials and Research UC Irvine discusses Chlorambucil v. Ibrutinib Shows Ibrutinib Powerful in Older Patients with CLL from ASH 2015
Susan M. OBrien, MD Medical Director of the Sue and Ralph Stern Center for Cancer Clinical Trials and Research UC Irvine talks about the Adverse Events with Idelalisib + Rituximab May Be Autoimmune Related from ASH 2015
Aaron Gerds, MD Taussig Cancer Institute, Department of Hematology & Medical Oncology Cleveland Clinic discusses Imetelstat Pilot Study Data Released for MPN Patients
Aaron Gerds, MD Taussig Cancer Institute, Department of Hematology & Medical Oncology Cleveland Clinic discusses the PRM-151 Phase III Study Results in Myelofibrosis
Aaron Gerds, MD Taussig Cancer Institute, Department of Hematology & Medical Oncology Cleveland Clinic discusses the PERSIST-1 Phase III Study Results of Pacritinib from ASH 2015
Aaron Gerds, MD Taussig Cancer Institute, Department of Hematology & Medical Oncology Cleveland Clinic discusses how the COMFORT II Study Shows Ruxolitinib as a Very Durable Treatment for MPN from ASH 2015
Mitchell Smith, MD Director of the Lymphoid Malignancies at Cleveland Clinic Taussig Cancer Institute discusses Real World Experience with Approved BCR Signaling Inhibitors at ASH 2015
Mitchell Smith, MD Director of the Lymphoid Malignancies at Cleveland Clinic Taussig Cancer Institute discusses R-CHOP With or Without Bortezomib Results at ASH 2015
Mitchell Smith, MD Director of the Lymphoid Malignancies at Cleveland Clinic Taussig Cancer Institute discusses the New CAR T-Cell Studies Launching Now from ASH 2015
Mitchell Smith, MD Director of the Lymphoid Malignancies at Cleveland Clinic Taussig Cancer Institute discusses Natural Therapeutic Partners for BCR Signaling Inhibitors at ASH 2015
Mitchell Smith, MD Director of the Lymphoid Malignancies at Cleveland Clinic Taussig Cancer Institute discusses Ibrutinib in Mantle Cell Lymphoma report from ASH 2015
Mitchell Smith, MD Director of the Lymphoid Malignancies at Cleveland Clinic Taussig Cancer Institute discusses Atrial Fibrillation in Patients with CLL report from ASH 2015
Mitchell Smith, MD Director of the Lymphoid Malignancies at Cleveland Clinic Taussig Cancer Institute discusses ABT-199 Data Released at ASH 2015
Steven T. Rosen, M.D. Director of the Comprehensive Cancer Center City of Hope discusses Real World Experience with Ibrutinib and Idelalisib from ASH 2015
Steven T. Rosen, M.D. Director of the Comprehensive Cancer Center City of Hope talks about Novel Nucleoside Analog Ribose Sugar in AML at ASH 2015
Steven T. Rosen, M.D. Director of the Comprehensive Cancer Center City of Hope talks about Map Kinase Pathway P-38 in CLL
Steven T. Rosen, M.D. Director of the Comprehensive Cancer Center City of Hope discusses Choosing a BCR Signaling Inhibitor in CLL from ASH 2015
Steven T. Rosen, M.D. Director of the Comprehensive Cancer Center City of Hope talks about ASH 2015 Highlights for Myeloma Treatments
Steven T. Rosen, M.D. Director of the Comprehensive Cancer Center City of Hope discusses the latest Advances In B-Cell Lymphoma From ASH 2015
Jennifer R. Brown, MD Director, Chronic Lymphocytic Leukemia Center Dana-Farber Cancer Institute discusses Second Generation B2K Inhibitors Look Promising ACP-196 & BGB-3111 at ASH 2015
Jennifer R. Brown, MD Director, Chronic Lymphocytic Leukemia Center Dana-Farber Cancer Institute discusses Scientific Rational for 2 month lead-in of Idelalisib Prior to Initiation of Ofatumumab in CLL
Jennifer R. Brown, MD Director, Chronic Lymphocytic Leukemia Center Dana-Farber Cancer Institute talks about Real World Experience with Idelalisib – Rituximab Combination for Relapsed CLL
Jennifer R. Brown, MD Director, Chronic Lymphocytic Leukemia Center Dana-Farber Cancer Institute discusses Idelalisib + Ofatumumab as First Line Therapy for Patients with CLL at ASH 2015
Jennifer R. Brown, MD Director, Chronic Lymphocytic Leukemia Center Dana-Farber Cancer Institute talks about How the Idelalisib+Ofatumumab Trial Affect Planning in CLL
Dr. Joshua Brody, MD @joshuabrodyMD Director, Lymphoma Immunotherapy Program Icahn School of Medicine at Mount Sinai discusses Redistribution Lymphocytosis in CLL
Dr. Joshua Brody, MD @joshuabrodyMD Director, Lymphoma Immunotherapy Program Icahn School of Medicine at Mount Sinai talks about Utilizing Idelalisb and Ibrutinib in CLL at ASH 2015
Dr. Joshua Brody, MD @joshuabrodyMD Director, Lymphoma Immunotherapy Program Icahn School of Medicine at Mount Sinai talks about Combining Antibody TherapyWith BTK Inhibitor in Folicular Lymphoma at ASH 2015
Press brief by Mark C. Walters, MD, at the American Socitety of Hematology (ASH) 2015 annual meeting. Dr Walters provides an update on the Northstar study of subjects treated with the LentiGlobin BB305 Drug Product. Previously reported early results in subjects with ?-thalassemia major participating in the ongoing HGB-205 and HGB-204 (Northstar) studies suggest that transplantation with autologous CD34+ cells transduced with a replication-defective, self-inactivating LentiGlobin BB305 lentiviral vector containing an engineered ?A-T87Q?globin gene (LentiGlobin BB305 Drug Product) has a positive safety profile and leads to ?A-T87Qglobin production and can lead to transfusion independence.
Dr. Joshua Brody, MD @joshuabrodyMD Director, Lymphoma Immunotherapy Program Icahn School of Medicine at Mount Sinai discusses Chimeric Antigen Receptor T-Cells from ASH 2015
Dr. Joshua Brody, MD @joshuabrodyMD Director, Lymphoma Immunotherapy Program Icahn School of Medicine at Mount Sinai gives an Update of Combining Immunotherapy with Targeted Therapies an Update from ASH 2015
Dr. Joshua Brody, MD @joshuabrodyMD Director, Lymphoma Immunotherapy Program Icahn School of Medicine at Mount Sinai gives and update on Checkpoint Blockade from ASH 2015
Dr. Joshua Brody, MD – @joshuabrodyMD Director, Lymphoma Immunotherapy Program Icahn School of Medicine at Mount Sinai discusses an update on BCR signaling inhibitors in CLL at ASH 2015
Press brief by James N. Kochenderfer, MD, at the American Socitety of Hematology (ASH) 2015 annual meeting. Dr Kochenderfer provides an overview of a trial of allogeneic T-cells that were genetically engineered to express a chimeric antigen receptor (CAR) targeting the B-cell antigen CD19.
At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Ali Hodge, Advanced Nurse Practitioner for Acute Oncology at The Royal Marsden NHS Foundation Trust, London, UK, discusses an audit of the modified UKONS telephone triage tool that has been implemented for the Acute Oncology Service at The Royal Marsden Hospital. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
Join us for a provocative program format that includes point and counterpoint presentations and interactive case discussions to provide varied perspectives on new data, guideline changes, and expert recommendations in multiple myeloma. Interact with international experts as they debate clinical questions and discuss how these challenges affect therapeutic decisions faced by clinicians treating myeloma.
Dr. Morie Gertz of the Mayo Clinic shares his overview of this year’s American Society of Hematology (ASH) meeting. He talks about Dr. Brian Durie’s discussion of three-drug treatment providing longer overall survival in newly diagnosed multiple myeloma patients versus two-drug treatment. He also discusses the recent advances in oral agents to treat multiple myeloma.
Dr. Sagar Lonial of the Winship Cancer Institute of Emory University in Atlanta, Georgia, speaks from the American Society of Hematology’s (ASH) national conference this weekend. In this video, Dr. Lonial discusses the excitement at ASH about two-drug versus three-drug treatment approaches in newly diagnosed myeloma patients.
Dr. Kenneth Anderson of the Dana-Farber Cancer Institute and Vice President of the American Society for Hematology (ASH) shares about the exciting advances being discussed at the ASH annual conference this weekend in Orlando, Florida.